The synthesis and biological evaluation of novel series of nitrile-containing fluoroquinolones as antibacterial agents

被引：83
作者：
Murphy, Sean T.
Case, Heather L.
Ellsworth, Edmund
Hagen, Susan
Huband, Michael
Joannides, Themis
Limberakis, Chris
Marotti, Keith R.
Ottolini, Amy M.
Rauckhorst, Mark
Starr, Jeremy
Stier, Michael
Taylor, Clarke
Zhu, Tong
Blaser, Adrian
Denny, William A.
Lu, Guo-Liang
Smaill, Jeff B.
Rivault, Freddy
机构：
[1] Pfizer Global Res & Dev, La Jolla Labs, San Diego, CA 92121 USA
[2] Pfizer Global Res & Dev, Ann Arbor Labs, Ann Arbor, MI 48105 USA
[3] Univ Auckland, Sch Med Sci, Auckland Canc Soc Res Ctr, Auckland 1020, New Zealand
[4] Ecole Super Biotechnol Strasbourg, Dept Recepteurs & Prot Membranaires, UMR7175, Inst Gilbert Laustriat, F-67400 Illkirch Graffenstaden, France
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2007年 / 17卷 / 08期
关键词：
fluoroquinolones; antibacterial; resistance; nitriles; dofetilide; hERG; pK(a); PF-00951966; PF-02298732; PF-02789402;
D O I：
10.1016/j.bmcl.2007.01.090
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Several novel series of nitrile-containing fluoroquinolones with weakly basic amines are reported which have reduced potential for hERG (human ether-a-go-go gene) channel inhibition as measured by the dofetilide assay. The new fluoroquinolones are potent against both Gram-positive and fastidious Gram-negative strains, including Methicillin resistant Staphylococcus aureus and fluoroquinolone-resistant Streptococcuspneumoniae. Several analogs also showed low potential for human genotoxicity as measured by the clonogenicity test. Compounds 22 and 37 (designated PF-00951966 and PF-02298732, respectively), which had good in vitro activity and in vitro safety profiles, also showed good pharmacokinetic properties in rats. C 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2150 / 2155
页数：6
相关论文
共 18 条
[1]   The fluoroquinolones: How long will their utility last? [J].
Bakken, JS .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2004, 36 (02) :85-92
[2]   THE STEREOSPECIFIC SYNTHESIS OF (2S,3R) 3-CARBOXYPROLINE AND (2S,3R) 3-AMINOPROLINE [J].
BALDWIN, JE ;
ADLINGTON, RM ;
GOLLINS, DW ;
GODFREY, CRA .
TETRAHEDRON, 1995, 51 (17) :5169-5180
[3]   CATALYTIC EPOXIDATION OF ALKENES WITH OXONE [J].
DENMARK, SE ;
FORBES, DC ;
HAYS, DS ;
DEPUE, JS ;
WILDE, RG .
JOURNAL OF ORGANIC CHEMISTRY, 1995, 60 (05) :1391-1407
[4]   QUINOLONE ANTIBACTERIALS CONTAINING THE NEW 7-[3-(1-AMINOETHYL)-1-PYRROLIDINYL] SIDE-CHAIN - THE EFFECTS OF THE 1-AMINOETHYL MOIETY AND ITS STEREOCHEMICAL CONFIGURATIONS ON POTENCY AND INVIVO EFFICACY [J].
DOMAGALA, JM ;
HAGEN, SE ;
JOANNIDES, T ;
KIELY, JS ;
LABORDE, E ;
SCHROEDER, MC ;
SESNIE, JA ;
SHAPIRO, MA ;
SUTO, MJ ;
VANDERROEST, S .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (07) :871-882
[5]   Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding [J].
Fraley, ME ;
Arrington, KL ;
Buser, CA ;
Ciecko, PA ;
Coll, KE ;
Fernandes, C ;
Hartman, GD ;
Hoffman, WF ;
Lynch, JJ ;
McFall, RC ;
Rickert, K ;
Singh, R ;
Smith, S ;
Thomas, KA ;
Wong, BK .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (02) :351-355
[6]   7-AZETIDINYLQUINOLONES AS ANTIBACTERIAL AGENTS - SYNTHESIS AND STRUCTURE-ACTIVITY-RELATIONSHIPS [J].
FRIGOLA, J ;
PARES, J ;
CORBERA, J ;
VANO, D ;
MERCE, R ;
TORRENS, A ;
MAS, J ;
VALENTI, E .
JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (07) :801-810
[7]  
GRACHECK SJ, 1991, 31 INT C ANT AG CHEM
[8]  
GREENGRASS PM, 2003, Patent No. 2003021271
[9]   QT interval prolongation: And the beat goes on [J].
Jalaie, M ;
Holsworth, DD .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2005, 5 (12) :1083-1091
[10]  
Jia ZJ, 2001, ELECTROPHORESIS, V22, P1112, DOI 10.1002/1522-2683()22:6<1112::AID-ELPS1112>3.3.CO
12